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CHAPTER I
IN VITRO PENETRATION OF ACYCLOVIR
THROUGH CHICKEN SKIN MEMBRANES2
INTRODUCTION
The purpose for this research is to explore a new
method for drug administration to birds.Such a technique
might have great value in improving veterinary therapy.In
comparison of animal therapeutics, exotic birds is becoming a
significant and still growing sector of the veterinary patient
population (1).Avian medicine for exotic species remains,
however,in its infancy.Within the last ten years, many
avian diseaseshavebeen newlycharacterized,and many
medicationshaveseentheirfirstassessmentinavian
therapies (2).To evolve a system of medical treatments, new
therapeutic techniques must be developed to meet the needs of
avian biology. Conventional routesof therapy usedin
mammalian species are associated with great risk and /or low
efficacy.Intravenous injections are frequently followed by
hemorrhage, because the accessible veins are friable, and
vulnerable to trauma.Losses of blood even in these small
quantities (on the order of one to several ml) are significant
in birds because of their diminutive body sizes, therefore,
blood volumes.Oral administration may have the hazard of
accidental respiratory aspiration (3).In addition, it is
likely to be a less desirable route of administration in the
bird than in the mammal, because of their short length of
intestines, which limit the time available for drug absorption
(4).Transdermal absorption would by comparison offer greater3
safety in the technique of drug administration(5). The
kinetics of transdermal absorption might also offer advantages
intherapeuticefficacy,sincetheabsorption phaseis
prolonged over many hours.The high metabolic rates in birds
translate into faster metabolism in clearance of xenobiotics,
necessitating a higher dosing frequency than in mammals (6).
High dosing frequencies are not only inconvenient for flock
treatments, but they also engender a risk of imposing stress
on the patient as a result of the frequent handling and
restraint. Route of administration characterized by prolonged
absorption, as with transdermal administration would offer
importantadvantageinlowerdosagefrequencies thereby
decreasing the distress of restraint and the incidence of
treatment injury (5).Also, the convenience of combined with
the low dosage frequency topical application could make this
routeofadministrationanefficientmeansforflock
treatments.
Percutaneous absorption involves passive diffusion of
substance through the skin.Stratum corneum in the skin layer
is known as the main resistance (6).Generally, permeation by
the transdermal route first involves partitioning into the
stratum corneum.The rate of percutaneous absorption is
proportional directly to the drug concentration (dissolved in
itsvehicle), partitioncoefficient,anddiffusion
coefficient, inversely to skin thickness (6).Transdermal
absorption is expected to be successful in birds, more so than4
in mammals, because birds have much thinner skins (presenting
less of a barrier to penetration than in mammals) and small
body sizes(providing a desirable body volume to surface
ratio, which would allow the accumulation of therapeutically
significant drug concentrations) (3).
Pacheco's Parrot Disease (PPD)is a highly contagious
acute, and often fatal herpesviral infection which occurs in
psittacine birds (7).Clinical signs of PPD include: sudden
onset of lethargy, fluffing of the feathers, yellow urates,
and regurgitation.Seizures often occur in terminal stages of
the disease.Mortality rates can be as high as 100 percent in
some species of psittacine birds.Birds in excellent body
condition may be found dead without any prior clinic signs
(8) .
Acyclovir waschosenasamodelcompoundforthe
evaluation of transdermal absorption, because it is used to
treat the herpes virus of Pacheco's disease in Psittacine
birds.
Acyclovir (ACV)was discovered in 1974(9).Clinical
trials of ACV began in 1977 and the first topical form of the
drug was available to physicians in 1982 (9).ACV has been
used as an antiviral compound due to its low host cell
toxicity (10).The value of ACV has been documented in the
treatment of severe herpes simplex virus (HSV) infections in
immunosuppressed hosts and in primary genital HSV infection
uponitsadministrationeitherintravenously,orallyor5
topically (ii, 12).
Acyclovir occurs as a white, crystalline powder and has
solubilities of 1.3 mg/ml in water at 25°C and 0.2 mg/ml in
alcohol.The drug has pica's of 2.27 and 9.25 (13, 14) so it
is ionized at physiological pH's (Figure I.1) .Absorption of
orallyadministeredacyclovirisslow,variableand
incomplete.Its oral bioavailability is approximately 15-30%
(14).For topical use, acyclovir is commercially available as
an ointment in a polyethylene glycol vehicle (14).Clinical
failure has been reported for topical ACV treatmentin
patients(15,16).The rate ACV penetrates the stratum
corneum in these patientsis minimal and may not reach
infected cells in the lower layers of epidermis in adequate
concentrations for therapy (15).
Severalapproacheshavebeenusedtoimprovethe
percutaneous absorption of acyclovir (17, 18, 19, 20, 21).
Organic solvents {Ethanol(ET),Isopropanol(IPA), Propylene
glycol(PG) Isopropyl myristate(IPM)} have been reportedas
vehicles to improve penetration of topical acyclovir (17).
Cooper, et,al, demonstrated that the oleic acid and oleyl
alcohol, when added to the polar solvent PG, greatly improved
skin permeability to ACV (18) as did long-chain fatty acids
and alcohols in conjunction with PG (19).Dimethyl Sulfoxide
(DMSO) also accelerated the rate of skin penetration of ACV in
vitro using guinea pig skin (15).A modified aqueous cream
vehicle of 5% ACV (ACV-MAC) for the treatment of recurrentFigure 1.1Structure of acyclovir
Name: 9-[(2-Hydroxyethoxy)methyl]guanine
Formula: C8HIIN503
6
Molecular weight:225.21
Action: Antiviral.
Chemistry:White, crystalline powder;1.3 mg/ml in water at
25°C and 0.2 mg/ml in alcohol;Pka's 2.27 and
9.25;melting point 256°C.7
herpes labialis had superior cutaneous absorption relative to
the commercial topical ACV formulation(13). Therefore,
selecting a proper vehicle may enhance the penetration of
acyclovirbyfavoringdrugreleaseoralteringthe
physicochemical properties of skin membranes to alter drug
penetration (22, 23).
Percutaneous penetration enhancers have been shown to
improve the percutaneous absorption of ACV.Choi, et, al,
demonstratedthatthepermeationofACVincreased
systematically with increasing N-decylmethyl sulfoxide (NDMS)
concentration.The action of NDMS was assessed by pretreating
skin sections for various periods of time with the enhancer
and then assessing permeability (19).Five choline esters,
lauroylcholine, myristoylcholine, palmitoylcholine,
stearoylcholine and oleoylcholine were evaluated as skin
penetration enhancers of ACV by testing their effects on the
penetration of ACV across hairless mouse skin in vitro and
comparing the results to those obtained with oleic acid.The
results showed that the transdermal delivery of ACV, tested in
PG vehicle systems, could be significantly increased by adding
asmallamountofcholineestersoroleicacid.
Lauroylcholineandoleicacid werereportedtoactas
synergists giving larger enhancement of ACV than when used
separately (20).Compounds which contain an azacyclo ring
with terpene and/or alkyl chain group, for example: 1-dodecy-
lazacycloheptan-2-one(Azone),1-geranylazacycloheptan-2-one8
(7GU), 1-farnesylazacycloheptan-2-one(7FU) and 1-geranylaza-
cyclopentan-2-one(5GU),havebeenreportedaseffective
percutaneous penetration enhancers for ACV penetration through
excised hairless mouse and rat skin (17).The mechanism of
enhancer action for improving penetration of drugs might be
reversible removal of the resistance barrier of the stratum
corneum by modifying either the postulated lipid or polar
route through the skin or both, which permits the unhindered
access of a drug to the viable tissue and systemic circulation
(21, 22, 24).
The objective of this study involves development of
topical ACV formulations.The whole project was divided into
pilot (optimizing ACV vehicle systems) and target (cockatiel)
studies.Broiler hens, were chosen as an initial model to
decrease cost for initial studies determining the optimum
vehiclesystem andenhancersfrom numeroustopical ACV
formulations being tested before applying the results to the
more valuable cockatiels.In the pilot study, effects of
vehicles and the percutaneous absorption enhancers on the
penetrationofacyclovirfrom topicalformulations were
determined in the chicken lateral apteria skin model in vitro.9
MATERIALS AND METHODS
Materials and chemicals
Acyclovir(a gift) and Zovirax ointment 5% were obtained
from Burroughs Wellcome Co.,Research Triangle Park,NC;
Azone(1-dodecylazacycloheptan-2-one) was donated by Whitby
Res. Inc., Richmond VA; 7FU(1-farnesyl-g'caprolactam) and 7GU
(1-N-geranyl-g°caprolactam) as gifts were provided by Kuraray
Co., LTD. Japan;Saline was obtained form Abbott Lab. North
chicago, IL;Ethanol was obtained from Georgia Pacific Inc.,
Downmohan, WA;Propylene glycol (PG) and materials for o/w
cream base including Sesame oil, Glycerol monostearate, Tween
80, Span80, Trithenolmine and Carbopol 940 were obtained from
Merck &Co.,Inc. Rahway,NJ;Hypoxanthine and Isopropyl
myristate were obtained from Sigma Chemical Co., St. Louis,
MO);Broiler hens were raised and provided by Department of
Poultry Science, Oregon State University, Corvallis, OR.
Preparation of Skin Samples
Broiler hens weighing 1.2-1.9 Kg (5-7 weeks) were used in
thisstudy. Five chickens were sacrificed each day by
restraining them upside down in an inverted cone and slicing
through the neck to sever the jugular and carotidal vessels.
After plucking down the feathers, and removal of adherent fat,10
fascia, and skeletal muscle from the undersurface,ten pieces
of 6-7 cm2 lateral apteria skin samples were obtained and
placed on a gauze sponge.In order to keep skin fresh,
excised samples were laid on gauze sponge moistened with
physiological saline and sealed in a zip-locked plastic bag
(Baggies® sandwich bags).The bags were then placed on ice.
The skin was again cleaned in saline before being mounted in
the Franz diffusion cells.
Experimental Design
To optimize ACV penetration through chicken skin by
varying vehicles, enhancers, concentrations of acyclovir and
a penetration enhancer,experiments were performed among
forty-one topical ACV applications in three dosage forms
(suspension, o/w cream and a commercial ointment [Zovirax
Ointment 5%]) with three solvents making suspensions (Ethanol
[ET], Propylene Glycol [PG], and Isopropyl Myristate [IPM]),
an emulsion base and ointment(o/w cream base(21)and
PolyethyleneGlycol[PEG]base)andthreepenetration
enhancers {Atone, 7FU (1-farnesyl-r-caprolactam, and 7GU (1-N-
geranyl-g=caprolactam)1.It was a completely random design
with each treatment duplicated or repeated, and triplicate
replicationsforeachtreatment. Theformulaeand
experimental design are summarized in Table I.1.11
In vitro Percutaneous Penetration Experiment
Percutaneous penetration of ACV was studied in vitro in
an upright Franz diffusion cell.Samples were mounted in
donor cells with an available diffusion area of 3.14 cm2.The
receptor compartment of each cell was filled with 14 ml of
salineandstirredwithamagneticstirrer. Test
formulations, except the commercial ointment (Zovirax Ointment
5%), were prepared by (I) suspending acyclovir in solvent {ET,
PG or IPM) to an ACV dose of 4500 µg /ml (20 mM) or 9000 µ.g /m1
(40mM)1 with or without 0.2M of penetration enhancer, either
Azone,7FU or 7GU;(II) mixing acyclovir and an o/w cream
base to form 5% ACV cream, and then adding 0.0%, 1.0% or 2.0%
enhancer, either Azone, 7FU or 7GU.An ACV suspension (2.0m1)
orACVo/wcream5%(1.0g)wasappliedtothedonor
compartment, which was then sealed at the top with parafilm to
prevent evaporation.The diffusion cell was maintained at
37°C(±0.5°C)by circulating water around the cell from a
heated water bath.Selected sampling times were 0,1, 2, 4,
6,8,12and 20 hours after application of the topical
formulationtotheskinmembrane. Attheabovetime
intervals,0.8 ml of the receptor medium was withdrawn as a
sample and this volume was replaced with fresh medium.12
Analytical Assay for Penetration of Acyclovir
The amount of acyclovir penetrated was determined by HPLC
(M-15 Waters Associate Inc., MA).The mobile phase consisted
of a mixture of methanol and distilled water (10:90), the
column was SELECTISOL 10-cm C18 (5-micron, Phenomenex Inc.,
Torrance,CA).Detection was performed by UV (Model 440
Waters Associate Inc., MA) absorbance at 254 nm with a flow
rateof0.9ml/minandapressureof2100PSI,and
hypoxanthine (3.0 µg /m1) was used as the internal standard.
Samples obtained from receptor cells were analyzed after
filtration with a 5-/Am filter needle, and then centrifuged 8
min ataspeedof9000rpm which yields760gforce
(Centrifuge 5415C, Brinkmann Instruments, Inc. Germany).13
Table 1.1Experimental design for diffusion study
using chicken skin model
1. EFFECTS OF VEHICLES
4500geml
ACV
Off .1
CREAMI
5%
ACV:
PEG
BASE
2. EFFECTS OF ENHANCERS
A =4500µ4!m1 ACV;
B = 900014/m1 ACV
* = L0%;*. 2.0%-
ET
PG
IPM
AZONE* AZONE*
]CREAM 7FU* 7FU*k>
7GU* 7GU*
DOSAGE ACV FORMULA No. OF
FORM DOSE VEHICLE ENHANCER TESTS
4500gg/m1ET with 0.2MAzone 21
Suspension or PG or 17FU
9000µg /mlIIPM without 7GU 12
with 1.0%Azone
0/w cream5%(w/m) or 2.0% J7FU
or without 7GU 7
Ointment 5 %(w /w) PEG without 114
RESULTS AND DISCUSSION
Vehicle Effects on Penetration of Acyclovir
(I) Suspension The cumulative penetration of ACV suspended in
the solvents Ethanol, Propylene glycol or Isopropyl myristate
through chicken lateral atperia skin is presented in Table 1.2
and 1.3.The variation of cumulative ACV penetration among
the three solvents at twenty hours was significantly different
(P < 0.05).The solvent IPM allowed the maximum penetration
at doses 4500 pg/ml (20mM) and 9000 pg/ml (40mM) yielding a
cumulative amount penetrating through of 41.93 pg and 45.367
pg, respectively.The delivery of ACV varied among solvents
and ACV penetration through chicken skin ranked as follows:
IPM > ET > PG (Figure 1.2, 1.3).The vehicle IPM {(5=8.54
(cal/ce)1/2} is shown as the most hydrophobic compound among
the three selected solvents (Table 1.4), thus, the lipophilic
vehicle(5117,4=8.54)makes ACV penetrate through theskin
barrier easier than the vehicle (40=14.8) with hydrophilicity
does.The difference in penetration of acyclovir among these
vehiclesindicated the importance ofselectinga proper
vehicle.According to diffusion equation: M = P Cd t (6),
the extent of drug penetration (M) through skin membrane is
directly proportional to the concentration of that drug (Cd)
dissolved in a vehicle, the skin permeability (P = DK /h,), and
the diffusion time (t).Skin permeability (P) is a function15
of diffusion coefficient (D), partition coefficient (K), and
the thickness of stratum corneum(hsc)in the skin layer.
Therefore, the higher Cd and P, the smaller Ilse,the greater
amount of drug penetrates (6, 24). The vehicle effect can
influence either a direct action on skin permeability (in
improving D or K, or both), or altering drug solubility (Cd)
(17, 23, 25).
The variation of ACV penetration observed in different
vehicles without enhancer is smaller than with penetration
enhancerspresent(Tables1.5-1.11). Theextentof
enhancementof ACV penetration in different vehicles was
shown to change significantly with or without an enhancer
present(P<0.05).With the addition of a penetration
enhancer, the order for ACV penetration changed for the three
organic solvents listed: PG > ET > IPM instead of IPM > ET >
PG in a single vehicle.Since the greatest penetration was
observed with solvent PG and enhancer Azone (Figures I.5-
I.10), thecombinationof ahydrophilicsolvent
{6pG=14.8(cal/cm3)1/2} with a hydrophobic enhancer{ 6Azone=9-07
(cal/cm3)1/2}(Table1.4)is the desired combinstion for a
suspension vehicle.Therefore, vehicles can also affect the
action of the penetration enhancer, which added into that
vehicle, on the penetrant in the different extent.
(II) 0/w Cream and OintmentThe penetration of ACV from o/w
cream 5% and Ointment (Zovirax)5% is shown in Table 1.5.16
Acyclovir released sooner from the o/w emulsion occurred and
to a greater extent than from the commercial ointment during
the 20-hour study period.The total ACV penetration (23.86
Ag) was fivefold greater through chicken skin using o/w cream
as a vehicle than with an ACV ointment (Figure 1.4).There
was a greater than 12-hour lag time before acyclovir began
releasing from 5% ACV formulated in a Polyethylene glycol
(PEG) base.The clinical failures documented (11, 14) could
be in part due to poor penetration through skin of ACV in
adequate amounts for therapy using the commercial 5% ACV
ointment[Zovirax Ointment 5%). 0/w cream base(26)is
formulated using IPM, PG, ET,and surfactants Span80,
Tween80 in the vehicle.These may play a role as vehicles or
enhancers or both, thereby promoting ACV release from the o/w
cream (23).
Enhancer Effect on Penetration of Acyclovir
(I)Suspension Percutaneous penetration of acyclovir was
significantly (P<0.05) improved by addition of the penetration
enhancer.Tables 1.6-1.11 summarize topical ACV penetration
with or without enhancers.The slope of the ACV penetration
profile positively shifts when the suspension was prepared
with an enhancer of either Azone, 7FU or 7GU (Figure I.5-
I.10).The effect of penetration enhancers increases with
decreasinglipophilicityofthevehicle. Thegreatest17
enhancement in a suspension appeared when acyclovir was mixed
with Azone and PG.A promising amount of ACV penetration was
obtained from the binary vehicle with PG as the solvent and
enhancer Azone (Figure 1.5-1.10).The maximum cumulative
amount penetrating (88.40 ihg and 102.15 kcg ACV) appeared with
PG and Azone at an ACV dose of 4500 µg /ml (20mM) and 9000
µg /m1 (40mM), which was increased by over 85% of the total ACV
penetration compared to PG vehicle itself.The order of
enhancer effects on ACV released from the solvents among the
three selected enhancers was: Azone > 7FU > 7GU (Figure 1.13,
1.14). ExtentofenhancementinACVpenetrationwas
definitely affected by both the type of enhancers and vehicles
involved.The challenge is to select the optimal combination.
For acyclovir, the proper vehicle can be considered to combine
hydrophilic vehicle with lipophilic penetration enhancer (17).
The reason for the improvement was due to the drug being
applied in a binary vehicle system(organic solvent and
penetration enhancer),or use of the combination of the
percutaneous absorption promoter (Azone,7FU,7GU) and the
vehicle ET, PG and IPM, which in either instance may alter the
physicochemical properties of the skin barrier to increase the
permeability coefficient, or match acyclovir properties to
improve ACV solubility, or both (6, 23, 24).
(II)0/w CreamPercutaneous penetration enhancer improved
penetration of ACV over the o/w emulsion formulation without18
a penetration enhancer (Table 1.12).Comparing results from
5%ACV cream with or without the penetration enhancer,
percutaneous absorption of ACV increased by 60.93%, 68.52% and
53.84% with the addition of 2% of the penetration enhancer
Azone, 7FU or 7GU to the formulation, respectively (Figure
1.11, 1.12).7FU was the most effective enhancer for the o/w
cream formulations (Figure 1.13, 1.14).The extent of ACV
penetration was affected not only by the type of enhancer,
but the concentration of the enhancer added.The cumulative
penetration of ACV from a5%cream witha2%enhancer
increased 1.3 times over that when 1% enhancer was added
(Figure 1.11, 1.12).Thus, increasing the concentration of
thepercutaneousabsorptionenhancercanimproveACV
penetration (P<0.05).
Dose Effect on Penetration of Acyclovir
No statistical variation (P>0.05)in the rate of ACV
penetration through chicken skin were observed after doubling
ACV doses in topical ACV suspensions, although, the cumulative
ACV penetration from ACV suspensions increased with dose in
the presence of an enhancer (Figure 1.5-1.10).For example,
ACV dose in a ACV/ET suspension with 0.2M Azone increased from
4500 gg/ml (20mM) to 9000 gg/ml (40mM),the ACV penetration
at 20-hour also increased from 50.27 gg to 75.12 gg/ml.
Wester examined the effects of concentration on percutaneous19
absorption of nitroglycerin. Topical nitroglycerin dose
(Cd=10 mg/cm2) increased 10 times with the amount of material
becoming systemically available also increasing to 10 times
(23).Since acyclovir was prepared in a suspension, the
solubility of ACV may be kept constant at two ACV doses level
in the vehicle(single or binary),increasing amount of
applied drugs in suspensions does not alter the concentration
of acyclovir in that vehicle, and diffusion rate should be
constant, thus, dose effect did not affect ACV penetration at
P<0.05 experiment level.20
Table 1.2Cumulative penetration of acyclovir through
chicken skin from 4500 /4g/m1 ACV suspensions (n=6)
TIME ET PG IPM
(BR) (lug) (fig) (11g)
1 0.000 0.000 0.000
2 0.000 0.000 0.000
4 4.025±0.804 2.625±0.330 3.675±0.620
6 7.310±0.881 3.885±0.952 8.295±1.553
8 9.800±0.524 6.265±1.450 10.22±3.188
12 12.50±0.745 8.680±1.450 20.21±2.463
20 25.87±2.477 13.26±1.429 41.93±3.704
Table 1.3Cumulative penetration of acyclovir through
chicken skin from 9000 gg/ml ACV suspensions (n=6)
TIME
(BR)
ET
(/Lg)
PG
(Ag)
1PM
(/Lg)
1 0.000 0.000 0.000
2 0.000 0.000 0.000
4 3.920±0.581 3.896±0.837 4.736±0.732
6 5.572±0.819 5.740±0.501 7.980±0.806
8 8.876±0.843 8.144±1.152 11.25±0.701
12 12.82±0.608 10.64±1.155 23.77±1.322
20 26.12±2.348 14.69±1.217 45.36±3.356
Table 1.4 Solubility parameters of vehicles and enhancers17
Compound Solubility parameter (S)*
(cal/cm3) 112
Vehicle
Isopropyl myristate 8.54
Ethanol 12.6
Propylene glycol 14.8
Enhancer
Azone 9.07
7FU 9.10
7GU 9.21
*: S, solubility parameter, express the cohesion between
like molecules using as an index of compound polarity.
A large 6' means high hydrophilicity of the compound.21
Table 1.5Cumulative penetration of acyclovir (Ag) through
chicken skin from Zovirax 5% and o/w cream 5%
TIME
(HR)
ZOVIRAX
(n=6)
CREAM
(n=6)
1 0.000 0.000
2 0.000 0.000
4 0.000 3.570±0.580
6 0.000 6.534±0.994
8 0.000 8.074±1.686
12 0.000 10.92±1.492
20 4.470±1.502 23.29±4.178
Table 1.6Cumulative penetration of acyclovir (Ag) through
chicken skin from 4500 µg /ml ACV/ET
suspensions with 0.2M enhancers
TIME CONTROL
(HR)(n=5)
+AZONE
(n=6)
+7FU
(n=6)
+7GU
(n=6)
1 0.000 0.000 0.000 0.000
2 0.000 0.000 0.000 0.000
44.025±0.804 5.600±0.899 5.506±0.7705.012±0.410
67.315±0.8819.338±0.875 8.960±0.8698.166±0.970
89.800±0.524 12.67±0.423 12.09±0.630 11.74±0.829
1212.50±0.745 21.08±1.169 18.86±0.78415.42±0.543
2025.87±2.447 50.27±1.667 42.40±3.68935.16±2.548
Table 1.7Cumulative penetration of acyclovir (Ag) through
chicken skin from 9000 µg /ml ACV/ET
suspensions with 0.2M enhancers
TIME
(HR)
CONTROL
(n=6)
+AZONE
(n=6)
+7FU
(n=6)
+7GU
(n=6)
1 0.000 0.000 0.000 0.000
2 0.000 4.434±0.361 4.574±0.648 4.434±.0657
43.920±0.5818.600±0.539 7.560±1.559 6.930±1.084
65.572±0.819 13.17±0.770 11.06±1.596 9.194±0.678
88.876±0.843 23.91±0.261 18.74±1.162 12.61±0.449
1212.82±0.60839.70±1.504 29.25±3.417 20.34±2.150
2026.12±2.348 75.12±4.376 65.04±3.888 46.01±2.44322
Table 1.8Cumulative penetration of acyclovir (/Lg) through
chicken skin from 4500 pg/m1 ACV/PG
suspensions with 0.2M enhancers
TIME
(HR)
CONTROL
(n=6)
+AZONE
(n=6)
+7FU
(n=6)
+7GU
(n=6)
1 0.000 0.000 0.000 0.000
2 0.000 0.000 0.000 0.000
4 2.625±.330 8.190±1.886 5.624±0.6105.628±0.458
6 3.885±0.925 13.09±2.08910.50±1.184 8.428±1.007
8 6.265±1.45027.65±5.702 18.99±2.97912.32±0.995
128.680±1.45049.19±6.289 29.00±6.95826.32±2.295
2013.26±1.429 88.40±7.753 62.47±9.33851.16±4.763
Table 1.9Cumulative penetration of acyclovir (Ag) through
chicken skin from 9000 µg /m1 ACV/PG
suspensions with 0.2M enhancers
TIME
(HR)
CONTROL
(n=6)
+AZONE
(n=6)
+7FU
(n=6)
+7GU
(n=6)
1 0.000 0.000 0.000 0.000
2 0.000 7.070±1.0054.876±0.8235.904±1.135
4 3.896±0.837 10.73±1.812 8.190±1.46010.31±1.929
6 5.740±0.501 17.43±4.14816.06±1.47417.64±6.261
8 8.144±1.152 35.53±8.12029.95±1.83525.20±8.093
12 10.64±1.155 62.37±9.55152.03±5.10645.66±5.489
2014.49±1.217 102.2±6.47882.40±9.19069.30±2.471
Table I.10Cumulative penetration of acyclovir (Ag)
through chicken skin from 4500 Ag/m1
ACV/IPM suspensions with 0.2M enhancers
TIME
(HR)
CONTROL
(n=6)
+AZONE
(n=6)
+7FU
(n=6)
+7GU
(n=6)
1 0.000 0.000 0.000 0.000
2 0.000 0.000 0.000 0.000
4 3.675±0.620 5.600±0.9385.012±0.5284.788±0.400
6 8.295±1.553 10.27±1.2328.148±1.7817.604±1.194
8 10.22±3.188 19.09±0.97313.98±2.926 12.50±2.061
1220.21±2.363 28.09±4.66225.13±5.65920.93±1.109
2041.93±3.704 58.24±4.819 49.64±4.76743.06±5.58523
Table 1.11Cumulative penetration of acyclovir (gg)
through chciken skin from 9000 yg/ml
ACV/IPM suspensions with 0.2M enhancers
TIME CONTROL
(HR) (n=6)
+AZONE
(n=6)
+7FU
(n=6)
+7GU
(n=6)
1 0.000 0.000 0.000 0.000
2 0.000 5.040±0.3075.064±0.6714.516±0.623
4 4.376±0.732 8.354±0.4217.420±0.7467.884±0.615
6 7.980±0.806 12.11±0.834 10.41±0.564 12.24±0.906
8 11.25±0.70120.01±1.61714.40±1.064 18.24±4.598
1223.77±1.322 35.45±2.78227.50±2.70623.87±6.405
2045.36±3.356 78.70±7.09569.23±2.535 56.93±5.739
Table 1.12Cumulative penetration of acyclovir (yg)
through chicken skin from o/w cream
with or without enhancers
TIME
(HR)
CONTROL
(n=6)
+1%AZONE
(n=6)
+1%7FU
(n=6)
+1%7GU
(n=6)
1 0.000 0.000 0.000 0.000
2 0.000 2.975±0.6193.735±1.1492.824±0.410
4 3.570±0.580 5.548±0.8396.779±1.1404.900±0.895
6 6.534±0.994 10.42±1.680 10.78±1.992 6.744±1.119
8 8.074±1.686 17.36±5.37018.04±4.85711.26±1.016
1210.92±1.492 26.85±7.524 34.68±3.94114.16±1.765
2023.29±4.178 43.45±7.55655.56±3.84728.57±3.479
+2%AZONE +2%7FU +2%7GU
(n=6) (n=6) (n=6)
1 0.000 0.000 0.000
2 3.836±0.6234.648±1.220 3.804±0.888
4 7.280±1.4597.728±1.336 5.834±2.293
6 12.43±1.397 12.63±0.659 9.264±2.789
8 22.18±6.42323.99±2.72413.77±5.335
12 33.77±9.89739.76±9.31624.24±8.967
20 59.60±5.40872.89±9.06850.44±8.88624
TIME (HR)
Figure 1.2Effect of vehicles on Acyclovir penetration:
Cumulative penetration profile of acyclovir through excised
chicken skin from 4500 pg/m1 ACV suspensions withthree
organic vehicles in 20-hour diffusion study in vitro.Open
circle, vehicle Ethanol; filled circle, vehiclePropylene
Glycol; open triangle, vehicle Isopropyl Myristate.(n=5)25
4 8 12
TIME (HR)
16 20
Figure 1.3Effect of vehicle on Acvclovir penetration:
Cumulative penetration profile of acyclovirthrough excised
chicken skin from 9000 pg/ml ACV suspensionswith three
organic vehicles in 20-hour diffusionstudy in vitro.Open
circle, vehicle Ethanol; filled circle,vehicle Propylene
Glycol; open triangle, vehicle IsopropylMyristate. (n=6)26
30r-
TIME (HE)
Figure 1.4 gffect of vehicleon Acvclovir penetration: Cumulative penetrationprofile of acyclovirthrough excised chicken skin froma 5% ACV ointment (Zovirax)and a 5% ACV o/w cream in 20-hour diffusionstudy in vitro.Open circle, vehicle PolyethyleneGlycol; filled circle,vehicle o/w cream base. (n=6)AZONE
80 v 7FU
v ?GU
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Figure I.5 Xffect of Denetration enhancer on Acyclovir.
penetration:Cumulative penetration profile of. acyclovir
through excised chicken skin from 4500 pg /mi ACV suspensions
with vehicle Ethanol in 20-hour diffusion study in vitro.
Open circle, with no enhancer; filled circle, with Azone; open
triangle, with 7FU; filled triangle, with 7GU. (n=6)-r
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Figure 1.6 Jffect of penetration enhancer-on Acyclovir
penetration:Cumulative penetration profileof acyclovir
through excised chicken skin from 9000 pg/E1ACV suspensions
with vehicle Ethanol in 20-hour diffusionstudy in vitro.
Open circre, with no enhancer; filled circle,with Azone; open
triangle, with 7FU; filled triangle, with707. (n=6)100
C
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80
60
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Figure 1.7 Effect of penetration enhanceron Acyclovir
penetration:CUmulative penetration profileof acyclovir
through excised chicken skin from4500 pg/m1 ACV suspensions
with vehicle Propylene Glycol in20-hour diffusion study in
vitro.Open circle, with no enhancer; filledcircle, with
Azone; open-triangle, with 7FU; filled triangle,with 7GU.
(n=6)iwE
AZONE-
v 7FU
7GU
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Figure 1.8 Effect of penetrationenhancer on Acyclovir penetration:Cumulative penetrationprofile of acyclovir through excised chickenskin from 9000 pg/m1ACV suspensions with vehicle PropyleneGlycol in 20-hour diffusionstudy j vitro.Open circle, withno enhancer; filled circle,with Azone; open triangle, with7FU; filled triangle, with7GU. (n =6)80
60
40
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Figure 1.9 )ffect of penetration enhancer on Acyclovir
penetration:Cumulative penetration profile of acyclovir
through excised chicken skin from 4500 pg/ml ACV suspensions
with vehicle Isoproyl Myristate in 20-hour diffusion studyin
vitro.Open circle, with no enhancer; filled circle, with
Azone; open -triangle, with 7FII; filled triangle, with 703.
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Figure I.10Affect of penetration enhanceron Acvclovir
penetration:Cumulative penetration profile of acyclovir
through excised chicken skin from 9000pg/ml ACV suspensions
with vehicle Isoproyl Myristate in 20-hour diffusionstudy in
vitro.Open circle, with no enhancer; filled circle,with
Azone; open triangle, with 7FU; filled triangle, with7GU.601-
;
0
20
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Figure 1.11Effect of penetration enhancer on Acyclovir
penetration:Cumulative penetration profile of acyclovir
through excised chicken skin from 5% ACV o/wcreams with a 1%
enhancer in 20-hour diffusion study in vitro. Open circle,
with no enhancer; filled circle, .with Azone;open triangle,
with 7FU; filled triangle, with 7GU. (n=6)AZONE
7FU
v 7GU
o CONTROL
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Figure 1.12affect of penetration enhancer on Acyclovir
penetration:Cumulative penetration profile of acyclovir
through excised chicken skin from 5% ACV o/wcreams with a 2%
enhancer in 20-hour diffusion study in vitro.Open circle,
with no enhancer; filled circle, with Azone;open triangle,
with 7FU; filled triangle, with 7GU. (n=6)100
80
60
40
20
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Figure 1.13Effect of vehicle and penetrationenhancer on
Acyclovir penetration:The total penetration of acyclovir
through chicken skin from suspensions( ACV = 4500 pg/ml) and
o/w creams (5% ACV) with or withouta penetration enhancer
(Enhancer 0.2M in a susupension, 1.0% inan o/w cream).100
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Figure 1.14Effect of vehicle and penetration enhanceron
Acyclovir penetration:The total penetration of acyclovir
through chicken skin from suspensions ( ACV= 9000 pg/m1) and
o/w creams (5% ACV) with or withouta penetration enhancer
(Enhancer 0.2M in a susupension, 2.0% inan o/w cream).37
CONCLUSIONS
Thepercutaneousabsorption ofacyclovirfrom
suspensions, ointments and o/w creams with or without the
addition of penetration enhancer have been determined usinga
full-thickness lateral atperia fowl skin model.The effect of
vehicles on ACV penetration without enhancer was: IPM >ET >
PG in suspensions, and 0/w cream >> Ointment.All selected
penetration enhancers improved percutaneous absorption of ACV
through avian skin from all applied topical ACV formulations.
Azone provided the greatest enhancement from ACV suspensions,
and maximum penetration was observed in solvent PG with an
enhancer.The action of 7FU on ACV penetration from o/w cream
ACV 5% was shown to be the most effective, especially when
2.0% 7FU was applied.Therefore, the best topical delivery
medium for topical administration of acyclovir for treatment
of herpes virus infections in chickens is a suspension of
acyclovir in a vehicle of PG and an enhancer of Azoneor a
topical emulsion of a modified ACV o/w cream with 7FU.38
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IN VITRO PENETRATION OF ACYCLOVIR
THROUGH COCKATIEL SKIN MEMBRANES43
INTRODUCTION
Pacheco's Parrot Disease (PPD)is a highly contagious,
acute, and often fatal herpesviral infection which occurs
in psittacine birds such as quaker parakeets and cockatiels
(1). The signs of PPD usually follow a definite pattern.
Yellowish, watery diarrhea occurs 1-2 days and depression only
hours before death.When death occurs, it happens amazingly
fast.Frequently there is no diarrhea, with death occurring
acutely2-4hours after the warning sign of depression
appears.Acute death is the hallmark of Pacheco's disease
(2).Mortality rates can be as high as 100 percent in some
species of psittacine birds (3).The herpesvirus of Pacheco's
disease is shed in the feces and transmitted most often
orally, through contaminated food, in contaminated water, or
by preening contaminated plumage (2).There are two basic
sources of Pacheco's virus.One is a shedding, sick bird
before it dies.The other source is asymptomatic carriers
which are totally resistant to the disease but harbor the
virus.The incubation period for PPD is variable.The large
psittacines can show sighs within 41/2 days after exposure.On
the other extreme, the incubation period may extend into years
for other psittacines,with signs appearing when severe
stress occurs (2).
Acyclovir (ACV) is an antiherpesviral compound which has
low toxicity in uninfected host cells (3).The antiviral44
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Figure II. 1.Acyclovir phosphorylation by the cytoplasmic5' nucleotidase.
Mechanism:ACV interferes with DNA synthesis and inhibits
viral replication.45
effect of acyclovir on herpes simplex viruses and varicella
zoster virus has been found to result from its interference
with DNA synthesis and a selective inhibition of herpesvirus
replication (3,4).Acyclovir has in vitro activity against
some avian herpes viruses (5, 6, 7).IV or IM administration
of acyclovir was applied in treatment of PPD in Quaker
parakeets(8).It has also been reported to reduce the
incidence of experimentally induced herpes virus infections
(Marek'sdisease)inturkeys(9),butthetopical ACV
application in the treatment of herpesviral disease in avian
species has not been reported yet.The poor In vitro and in
vivo penetration of ACV from a topical5% ACV ointment
(commercially available) was reported using both human and
guinea pig skin models(3,4),and clinicalfailure was
observed in adequate ACV doses for therapy of herpesvirus
disease after topical administration (4).To increase the
penetration of topical ACV, various vehicles such as fatty
acids (10), organic solvents {N-decylmethyl sulfoxide (11),
Dimethylsulfoxide(12),Ethanol,Isopropanol,Propylene
glycol(13)1,a modified cream base(3,4),a transdermal
delivery patch (16)and penetration enhancers {Azone (13),
choline esters(15)1were used to improve percutaneous
absorption of topical ACV administration (14).
From the results of the pilot(chicken)study,the
greatest ACV penetration through fowl skin resulted from
both PGjenhancer suspensions and modified (with enhancers) o/w46
creamformulations. Moreover,thecombinationvehicle
PG/Azone was shown as the best medium for an ACV suspension,
and a cream/7FU base was the optimum for an ACV emulsion.In
this chapter, the research objective was to study penetration
ofacyclovirfromformulations which gave thegreatest
penetration in the pilot study through excised chicken skin
membranes. Theeffectofvehiclesandenhancerson
percutaneousabsorptionofacyclovirfrom those topical
formulations were re-evaluated in vitro using cockatiel skin
so as to provide and explore the feasibility to treat herpes
virus infection in psittacine species.47
MATERIALS AND METHODS
Materials and Chemicals
Acyclovir was donated generously by Burroughs Wellcome
Co., Research Triangle Park, NC;Azone (a gift) was obtained
from Whitby Res. Inc., Richmond, VA;7FU (1-farnesyl-g=capro-
lactam) as a gift was provided from Kuraray Co., LID. Japan;
Saline was obtained from Abbott Lab., North Chicago,IL;
Propylene glycol and the o/w cream base components such as
Sesameoil,Glycerolmonostearate,Tween80,Span80,
Trithanomine, Carbopol 940 were obtained from Merck & Co.,
Inc.,Rahway,NJ;Hypoxanthine was provided from Sigma
chemical Co., St. Louis, MO;Cockatiels were obtained from
Department of Veterinary Medicine, Oregon State University,
Corvallis, OR.
Preparation of Skin Samples
Ten cockatiels weighing 70-96 grams were sacrificed by
cervical dislocation.Twenty pieces of the full-thickness
lateral apteria skin samples were obtained after plucking
feathers and removing adipose tissue, fascia and skeletal
muscle from the undersurface.The excised skin was maintained
at 25°C and moistened with saline solution continuously until
used in the study.Vernier calliper (General Inc., USA) was48
used to measure the thickness of cockatiel skin samples.
Experimental Design
The experiment was performed as a random design with
three replications except for a PG/ACV suspension and 5% o/w
emulsion with enhancer where two replications were used.All
treatments were performed once due to limited skin samples.
In this study, an organic solvent PG and an o/w cream base
were selected as vehicles, and Azone and 7FU were added as
penetration enhancers.ACV dose was 4500 µ.g /ml or 9000 pg/m1
in a suspension, and 5%(w/w)in o/w creams.Details are
listed in Table II1.
In vitro Diffusive Penetration Study
Percutaneous penetration of ACV was determined by an in
vitro diffusion study.Samples were mounted on a diffusion
cell with a surface area of3.14cm2.14 ml of saline
solution was added into each receptor cell and stirred with a
magnetic stirrer.Applied test formulations were(I)20mM
(4500 pg) or 40mM (9000 pg) ACV suspensions with solvent PG
and 0.2M Azone or 7FU;(II) ACV o/w cream 5% with 2.0% Azone
or 7FU.The 2.0 ml suspension or 1.0 gram of o/w cream was
applied to the donor cell and the top sealed with parafilm.
The diffusion cell was kept at 37°C (±0.5°C) by a circulating49
water bath.Sampling times were chosen at 1, 2, 4, 6, 8, 12,
and 20 hours after application.0.8 ml of the receptor medium
was withdrawn and was replaced with the same volume of fresh
saline solution.
Assay of Acyclovir Penetration
Acyclovir assays were carried out with a high performance
liquid chromatograph (HPLC)(M-15 Waters Associate Inc., MA)
which was equipped with a 5-micron C18 column (Phenomenex
Inc.,CA)and UV detector(m-440 Waters Associate Inc.,
Milford, MA)operating at 254nm.The mobile phase was a
mixture of methanol and distilled water (10:90), at a flow
rate of 0.9 ml/min.Before analysis, samples obtained from
the receptor cell were filtered through a 5-Am filter needle
and centrifuged 8 min at 9000 rpm (or 760 g force) (Centrifuge
5415 C, Brinkmann Instruments Inc., Germany).Quantitation
was performed using peak area measurements for acyclovir in
the diffusate.Hypoxanthine 5.0 µg /ml was employed as the
internal standard.50
Table II.1Experimental design for ACV penetration
study using cockatiel skin model
FormulaVehicle ACV Dose
(µg /ml, %)
Enhancer
(0.2M)
Treatments
(n)
1 PG 4500 - 2
2 PG 4500 Azone 3
3 PG 4500 7FU 3
4 PG 9000 Azone 3
5 PG 9000 7FU 3
6 Cream Base 5%(w/w) Azone 2
7 Cream Base 5%(w/w) 7FU 251
RESULTS AND DISCUSSION
(I) SuspensionPercutaneous absorption of acyclovir through
cockatiel skin from PG solvent with or without the penetration
enhancer is shown in Table 11.2, and the penetration of ACV vs
time profiles are illustrated in Figure 11.2 and 11.3.A
significant difference in penetration of ACV was observed
between ACV suspensions withasolvent PG and PG with
penetration enhancer (P<0.05).Cumulative penetration of ACV
from a 20mM ACV/PG suspension was increased 26 fold by the
presence of penetration enhancer Azone, and 13 fold by 7FU
over ACV in PG solvent alone (Figure 11.3).ACV penetration
from suspension with enhancer Azone was enhanced by 51.40%
(20mM) and 42.62% (40mM) above the enhancement achieved by
7FU.Doubling the amount of ACV in the PG/enhancer suspension
from 20mM to 40mM caused the total ACV penetration to increase
43.3% to 51.98% for Azone and 7FU, respectively (Figure 11.2,
11.3).The enhancement may mainly be attributed to the binary
vehicle with an organic solvent and a penetration enhancer by
their improving the physicochemical properties of the skin to
penetration of acyclovir or altering the solubility of ACV, or
both (13, 14).Compared to effects of penetration enhancers,
Azoneprovidedthegreaterimprovementthan7FUfrom
PG/enhancer suspensions, therefore, the option of Azone as a
ACV promoter was preferable.ACV penetration using cockatiel
skin model was observed to be much greater in extent compared52
to penetration of chicken skin membrane, but the tendency of
penetration was similar.Diffusion equation (17) indicates
that the
thickness
cockatiel
thickness
thickness
rate of penetration is inversely proportional to
of the skin.The greater ACV penetrating through
skin may partly bedueto the differencein
ofcockatielskin(h=0.04cm)compared to the
of chicken skin membrane (h=0.12cm).Studies have
demonstrated that percutaneousabsorption appearstobe
greater when the drug is applied to skin witha thin horny
layer than with one that is thick due to the properties of the
stratum corneum difference in number of cell layers, stacking
of cells size, and amount of surface lipid (14).Therefore,
ACV penetration variation between chicken and cockatiel skin
maybe mainly attributed to different thicknesses of skin in
the two species.
(II) 0/w cream A comparative experiment between the effect of
enhancer(2.0%)Azone and 7FU was performed by in vitro
diffusion using cockatiel skin membranes.The analytical
results are reported in Table 11.3.ACV penetration from a
o/w cream with 7FU was 57.76% higher than that with Azone
(Figure 114).The ability of 7FU to increase ACV penetration
from o/w cream was 3.87 times greater over the extent of
improvement in ACV penetration by Azone (Figure 114).
Reviewing results of vehicle effects observed in Chapter
I, acyclovir penetration through chicken skin from suspension53
with IPM(6=8.54)was the greatest, however,the highest
improvement occurred in presence of PG solvent (6=14.8) with
enhancer Azone (6=9.07).Azone effect in ACV suspensions was
shownstronger withahydrophilic vehiclethan witha
lipophilic medium, while, the action of 7FU on o/w cream was
the most important.The o/w cream base was formulated by
thirteen kinds of compounds (Table 11.4) in an oil-in-water
combination type, ACV may dissolve in both oil and water
phases in a different extent, thus, the action of enhancers on
this combination vehicle maybe different from that in an
unique phase in a single vehicle like solvent PG.7FU was
shown as the best in o/w cream formulations, probably because
it had greater effect than Azone on both parts (oil and water
phase) of the combination vehicle.
The major reason for the alteration in ACV penetration
across species was due to variation of the thickness of skins
between chickens and cockatiels (14).54
Table 11.2Cumulative penetration of acyclovir (pg) through
cockatiel skin from ACV/PG suspensions
with or without 0.2M enhancers
TIME DOSE 4500pg/m1
CONTROL +AZONE +7FU
(n=2) (n=3) (n=3)
1 0.000 14.84±3.661 6.020±1.372
2 2.800±1.980 32.85±10.85 12.26±0.277
4 5.320±0.792 81.48±20.69 20.44±0.792
6 7.210±0.693 129.6±11.34 46.55±17.72
8 8.740±0.434 192.7±41.29 71.84±20.58
12 9.870±1.484 229.5±33.28 119.8±12.67
20 15.12±0.594 390.9±23.37 190.0±32.07
DOSE 9000µq /ml
+AZONE +7FU
(n=3) (n=3)
1 73.64±9.240 31.36±15.42
2 155.4±29.13 47.04±17.53
4 218.0±12.45 77.90±25.28
6 286.3±10.65 112.7±25.06
8 387.7±11.17 196.2±36.44
12 522.6±31.46 242.2±39.20
20 689.6±25.34 395.7±17.90
Table 11.3Cumulative penetration of acyclovir (pg) through
cockatiel skin from o/w cream 5%
with 0.2M enhancers
TIME +AZONE +7FU
(HR) (n=2) (n=2)
1 9.030±2.079 30.94±1.284
2 11.06±3.168 45.78±1.582
4 21.98±4.357 63.21±9.212
6 32.62±6.038 95.41±20.09
8 45.78±7.326 127.9±10.79
12 64.96±3.959 194.0±7.920
20 120.1±8.414 282.2±18.4155
Table 11.4Emulsion bases of topical ACV formulations
Materials Percentage
1. 01W Cream base:
A. Sesame oil 6.0
Glycerol monostearate 2.0
Tween 80 1.5
Span80 0.5
Isopropyl myristate 2.0
Triethanolamine 0.5
B. Distilled Water 75.5
Propylene glycol 6.0
Carbopol940 0.75
Ethanol 5.0
Preservative 0.3
2.Ointment base:
Polyethylene glycol 100700
C5 t
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Figure 11.2 Effect of penetration enhanceron Acyclovir
penetration:Cumulative penetration profile of acyclovir
through excised cockatiel skin from 4500 pg/m1 ACV suspensions
with vehicle Propylene Glycol in 20-hour diffusionstudy in
vitro.Open circle, with no enhancer; filled circle, with
Azone; open triangle, with 7FU; (n=3)700L
600 -
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Figure 11.3 effect of penetration enhanceron Acyclovir
penetration:Cumulative penetration profile of acyclovir
through excised cockatiel skin from 9000 pg/m1 ACV suspensions
with vehicle Propylene Glycol in 20-hour diffusionstudy in
vitro. Filled circle, with Azone;open triangle, with 7FU;
(n=3)58
TIME (HR)
Figure 11.4Effect of penetration enhancer on Acyclovir
penetration:Cumulative penetration profile of acyclovir
through excised cockatiel skin from 5% ACV o/wcreams with.a
2% enhancer in 20-hour diffusion study in vitro.Filled
circle, with Azone; open triangle, with 7FU; (n=2)C9 600
w 500
cc
400
300
0
_j<200
01_100
PG +40ACV PG +20ACV
VEHICLE
CREAM5%
59
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CONTROL
Figure 11.5 Effect of vehicle and penetration enhancer on
Acyclovir penetration:The total penetration of acyclovir
through cockatiel skin from PG suspensions (ACV dose: 40mM
[9000 Ag/m1] or 20 mM [4500 Ag/m1]) and 5% o/w creams with
or withoutapenetration enhancer(Enhancer0.2Mina
susupension, 2.0% in an o/w cream).60
CONCLUSIONS
Percutaneousabsorptionofacyclovirbyinvitro
diffusion through cockatiel skin membranes was determined.
ACV penetration from a suspension containing the solvent PG
wasdramaticallyimproved by additionofapenetration
enhancer, either Azone or 7FU.Azone was shown more effective
than 7FU in increasing passage of ACV through cockatiel skin
membrane from its PG suspension.Also, in the PG solvent
with an enhancer, ACV penetration increased with increasing
ACVpresentinthesuspension. ForACVo/wcream
formulations,the effect of 7FU was greater than Azone in
increasing penetration of ACV across cockatiel skin membrane.
A 40mM ACV suspension in PG and 0.2M Azone, or a 5% ACV
in an o/w emulsion cream base with 2.0% 7FU may provide
sufficient release and penetration of ACV for treatment of
herpes virus infection in cockatiels. Such a study should be
carried out to verify these conclusions.61
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